Immunization with GP1 but Not Core-like Particles Displaying Isolated Receptor-Binding Epitopes Elicits Virus-Neutralizing Antibodies against Junín Virus.
GP1
Junín virus
arenavirus
glycoprotein
immune response
neutralizing antibodies
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
22 Jan 2022
22 Jan 2022
Historique:
received:
13
12
2021
revised:
18
01
2022
accepted:
19
01
2022
entrez:
26
2
2022
pubmed:
27
2
2022
medline:
27
2
2022
Statut:
epublish
Résumé
New World arenaviruses are rodent-transmitted viruses and include a number of pathogens that are responsible for causing severe human disease. This includes Junín virus (JUNV), which is the causative agent of Argentine hemorrhagic fever. The wild nature and mobility of the rodent reservoir host makes it difficult to control the disease, and currently passive immunization with high-titer neutralizing antibody-containing plasma from convalescent patients is the only specific therapy. However, dwindling supplies of naturally available convalescent plasma, and challenges in developing similar resources for other closely related viruses, have made the development of alternative antibody-based therapeutic approaches of critical importance. In this study, we sought to induce a neutralizing antibody response in rabbits against the receptor-binding subunit of the viral glycoprotein, GP1, and the specific peptide sequences in GP1 involved in cellular receptor contacts. While these specific receptor-interacting peptides did not efficiently induce the production of neutralizing antibodies when delivered as a particulate antigen (as part of hepatitis B virus core-like particles), we showed that recombinant JUNV GP1 purified from transfected mammalian cells induced virus-neutralizing antibodies at high titers in rabbits. Further, neutralization was observed across a range of unrelated JUNV strains, a feature that is critical for effectiveness in the field. These results underscore the potential of GP1 alone to induce a potent neutralizing antibody response and highlight the importance of epitope presentation. In addition, effective virus neutralization by rabbit antibodies supports the potential applicability of this species for the future development of immunotherapeutics (e.g., based on humanized monoclonal antibodies). Such information can be applied in the design of vaccines and immunogens for both prevention and specific therapies against this and likely also other closely related pathogenic New World arenaviruses.
Identifiants
pubmed: 35214632
pii: vaccines10020173
doi: 10.3390/vaccines10020173
pmc: PMC8874384
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : University of Buenos Aires
ID : 20020190100013BA
Organisme : Agencia de Promoción Científica y Tecnológica
ID : PICT-2017- 1136
Organisme : Ministry of Education and Training - Vietnam International Education Development
ID : 933/QĐ-BGDĐT
Organisme : Friedrich-Loeffler-Institut
ID : Intramural
Références
J Virol. 1992 Jan;66(1):106-14
pubmed: 1370083
Vaccine. 2010 Jul 5;28(30):4713-8
pubmed: 20452431
Nat Struct Mol Biol. 2010 Apr;17(4):438-44
pubmed: 20208545
Acta Crystallogr D Biol Crystallogr. 2006 Oct;62(Pt 10):1243-50
pubmed: 17001101
J Gen Virol. 1989 May;70 ( Pt 5):1125-32
pubmed: 2471803
Front Cell Infect Microbiol. 2017 Feb 06;7:20
pubmed: 28220142
Nature. 2007 Mar 1;446(7131):92-6
pubmed: 17287727
Emerg Microbes Infect. 2020 Dec;9(1):1080-1091
pubmed: 32471334
Antiviral Res. 2018 Sep;157:140-150
pubmed: 30031760
Curr Opin Virol. 2019 Aug;37:77-83
pubmed: 31323506
Hum Vaccin. 2011 Jun;7(6):694-700
pubmed: 21451263
Front Immunol. 2021 Mar 11;12:637982
pubmed: 33777030
Adv Virus Res. 1998;50:141-82
pubmed: 9520999
Viruses. 2021 Mar 26;13(4):
pubmed: 33810465
Nature. 2018 Nov;563(7732):559-563
pubmed: 30464266
Lancet. 1984 Aug 4;2(8397):255-6
pubmed: 6146809
Viruses. 2012 Oct 17;4(10):2162-81
pubmed: 23202458
Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):1915-20
pubmed: 10051569
Cell Host Microbe. 2015 Dec 9;18(6):705-13
pubmed: 26651946
Proc Natl Acad Sci U S A. 2017 Jul 3;114(27):7031-7036
pubmed: 28630325
Mol Cell. 1999 Jun;3(6):771-80
pubmed: 10394365
Nat Commun. 2018 May 14;9(1):1884
pubmed: 29760382
Antiviral Res. 2018 Aug;156:21-28
pubmed: 29870772
Front Immunol. 2018 Mar 21;9:598
pubmed: 29619034
Proc Natl Acad Sci U S A. 2012 Mar 20;109(12):E690-7
pubmed: 22366317
Biomedica. 2002 Sep;22(3):287-95
pubmed: 12404929
Mol Ther. 2019 Mar 6;27(3):661-672
pubmed: 30713086
Int J Biol Macromol. 2020 Nov 15;163:1240-1248
pubmed: 32668306
J Virol. 2016 Jan 20;90(7):3515-29
pubmed: 26792737
NPJ Vaccines. 2020 Aug 4;5(1):71
pubmed: 32802410
J Virol. 2008 Jun;82(12):6045-51
pubmed: 18400865
Viruses. 2015 Jul 29;7(8):4204-29
pubmed: 26230706
Nat Commun. 2020 Jan 3;11(1):67
pubmed: 31900422
Antiviral Res. 2020 Feb;174:104666
pubmed: 31760108
Viruses. 2014 Feb 07;6(2):640-60
pubmed: 24513568
Sci Rep. 2017 Feb 13;7:42500
pubmed: 28211908
Antiviral Res. 2019 Mar;163:106-116
pubmed: 30668977
Curr Top Microbiol Immunol. 2002;262:65-74
pubmed: 11987808
Protein Expr Purif. 2011 Feb;75(2):218-24
pubmed: 20854910
Nat Rev Microbiol. 2019 Oct;17(10):593-606
pubmed: 31341272
Am J Trop Med Hyg. 1994 Nov;51(5):554-62
pubmed: 7985747
Biologicals. 2001 Sep-Dec;29(3-4):209-13
pubmed: 11851317
MAbs. 2017 Apr;9(3):419-429
pubmed: 28165915
Annu Rev Virol. 2017 Sep 29;4(1):141-158
pubmed: 28645238
Expert Rev Vaccines. 2009 Nov;8(11):1565-73
pubmed: 19863249
J Virol. 2019 Apr 3;93(8):
pubmed: 30728269
Nature. 2020 Dec;588(7839):682-687
pubmed: 33045718
J Virol. 2021 Aug 10;95(17):e0186820
pubmed: 34132574
J Virol. 2012 Apr;86(7):4024-8
pubmed: 22278244
Proc Natl Acad Sci U S A. 2021 Mar 16;118(11):
pubmed: 33836604
J Gen Virol. 2016 Mar;97(3):571-580
pubmed: 26684324
Sci Rep. 2017 Aug 29;7(1):9630
pubmed: 28851900
J Med Virol. 2003 Mar;69(3):447-50
pubmed: 12526057
Science. 1993 Nov 26;262(5138):1448-51
pubmed: 8248784